Search

Displaying results 4681 - 4690 of 10000 in total
  1. Drug

    Cefmenoxime

    go.drugbank.com/drugs/DB00267
    Approved

    It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria. … Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections.

  2. Drug

    Azelnidipine

    go.drugbank.com/drugs/DB09230
    Investigational

    It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increase in heart rate, unlike some other calcium channel blockers [L1379].

    International brands: Azelnidipine JG, Azelnidipine KOG
  3. Drug

    Neocartilage

    go.drugbank.com/drugs/DB05257
    Investigational

    Neocartilage is the only scaffold-free living cartilage graft on the market.

  4. Drug

    G207

    go.drugbank.com/drugs/DB05827
    Investigational

    G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG. … These viruses are specific herpes simplex viruses, or HSVs, generally known as the cause of cold sores.

    Synonyms: G 207, G-207
  5. Drug

    Daleuton

    go.drugbank.com/drugs/DB00154
    InvestigationalNutraceutical

    A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.

  6. Drug

    Amuvatinib

    go.drugbank.com/drugs/DB12742
    Investigational

    Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. … Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.

  7. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease. … ) and on other risk factors such as hypertension or diabetes.

  8. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  9. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    [L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603]

  10. Drug

    Human papillomavirus type 11 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10300
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces